A Study of SHR-A1811 in Subjects With Ovarian Cancer
This is an open-label study to evaluate the safety and efficacy of SHR-A1811 for injection in subjects with ovarian cancer.
Ovarian Cancer
DRUG: SHR-A1811|DRUG: Paclitaxel Injection|DRUG: Doxorubicin Hydrochloride Liposome Injection|DRUG: Gemcitabine Hydrochloride for Injection|DRUG: Topotecan Hydrochloride for Injection
Progression free survival (PFS), From day 1 to 10 months.
Objective response rate (ORR), From day 1 to 12 months.|Disease control rate (DCR), From day 1 to 12 months.|Duration of response (DOR), From day 1 to 12 months.|Overall survival (OS), From day 1 to 12 months.|Response rate (RR), From day 1 to 12 months.|Adverse events (AEs), From day 1 to 40 days after the last dose.
This is an open-label study to evaluate the safety and efficacy of SHR-A1811 for injection in subjects with ovarian cancer.